Webinar January, 2017

iPSC-derived Cell Models for Oncology Applications

Recorded January 25, 2017 

The recording of the webinar is available in full length here:

Webinar Q&A session – answers from presenters
Webinar Description:

Early prediction of drug-induced toxicity is needed in the pharmaceutical and biotechnology industries to decrease late-stage drug attrition. Specifically, oncology drugs have become more effective in extending the lives of patients suffering from cancer. This improved prognosis, however, is giving more time for anti-cancer drugs to exert toxic effects such as cardiotoxicity, neuropathy and more. Novel human cell models, such as human induced pluripotent stem cell (iPSC)-derived cell types, are needed to reliably and cost-effectively predict drug-related toxicities at the preclinical stage. iPSC-derived cells provide a flexible, high value human cellular system that offers a highly translational and typically more predictive cellular environment than immortalized cell lines or even primary rodent models. This webinar will describe proof-of-concept studies of how induced pluripotent stem cell-derived cells can predict cardiac and neuronal side effects caused by oncology compounds Register now and discover how human cardiac and neuronal cells, derived from induced pluripotent stem cells (iPSC), are playing a rapidly increasing role in in vitro safety and discovery approaches for oncology compounds. Whether you are screening for new oncology drug targets, or investigating drug effects on cellular structure or function, this webinar will provide insights for your own research.

Learning Objectives:

Learn how iPSC-derived cell types are used in oncology-related screening/safety applications, and how they help “humanizing” drug discovery / development

Gain insight into 'real-world' examples / case studies from experts in the area of cardio- and neuro-oncology

Understand how Axiogenesis’ products and services support your cardio- and neurotoxicity-related applications

Axiogenesis background / overview, products/services

 
Speakers:

Eileen Dolan, PhD,

Professor of Medicine, Section of Hematology/Oncology,

University of Chicago

 

Ivan Kopljar, PhD,

Scientist at Janssen,

Pharmaceutical Companies of Johnson & Johnson

 

Greg Luerman, PhD,

Technical Director, North America,

Axiogenesis

 

Moderator:

Joanna Smart

Host

Business Review Webinars

FIND US

Nattermannallee 1, Bldg S20
50829 Cologne
Germany –  (Map)

600 W Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
USA – (Map)

EMAIL US

Orders: order@axiogenesis.com
Support: support@axiogenesis.com
Other: office@axiogenesis.com

FOLLOW US

Twitter:  |   LinkedIn:  |   Newsletter:  Subscribe Axiogenesis Newsletter

CALL US

Phone (Main)
+49 221 99 88 18-0

Phone (US)
+1 844-511-6959

Fax + 49 221 99 88 18-10